Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
Launches With $68m Series A
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
